The overall response rate (ORR) stood at 37.1%, the median PFS was 6.8 months, and the median overall survival (OS) reached 12.3 months.370 Based on these positive results, sotorasib was granted breakthrough designation by the U.S. Food and Drug Administration (FDA) in May 2021, specifically for treating adults with locally advanced or metastatic NSCLC with a KRAS-G12C mutation, who have progressed after at least 1 prior line of systemic therapy. Here, KRAS is linked to non-small cell lung carcinoma.